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Hyaluronic acid (HA), the only non-sulphated glycosaminoglycan, serves numerous structural and
biological functions in the human body, from providing viscoelasticity in tissues to creating hydrated
environments for cell migration and proliferation. HA is also involved in the regulation of
morphogenesis, inflammation and tumorigenesis through interactions with specific HA-binding proteins.
Whilst the physicochemical and biological properties of HA have been widely studied for decades, the
exact mechanisms by which HA exerts its multiple functions are not completely understood.
Glycopolymers offer a simple and precise synthetic platform for the preparation of glycan analogues,
being an alternative to the demanding synthetic chemical glycosylation. A library of homo, statistical
and alternating HA glycopolymers were synthesised by reversible addition–fragmentation chain transfer
polymerisation and post-modification utilising copper alkyne–azide cycloaddition to graft orthogonal
pendant HA monosaccharides (N-acetyl glucosamine: GlcNAc and glucuronic acid: GlcA) onto the
polymer. Using surface plasmon resonance, the binding of the glycopolymers to known HA-binding
peptides and proteins (CD44, hyaluronidase) was assessed and compared to carbohydrate-binding
proteins (lectins). These studies revealed potential structure-binding relationships between HA
monosaccharides and HA receptors and novel HA binders, such as Dectin-1 and DEC-205 lectins. The
inhibitory effect of HA glycopolymers on hyaluronidase (HAase) activity was also investigated suggesting
GlcNAc- and GlcA-based glycopolymers as potential HAase inhibitors.
Introduction
Hyaluronic acid (HA) is a unique member of the glycosaminoglycan
(GAG) family1 which are linear polysaccharides containing a
core repeating disaccharide unit. The HA disaccharide consists
of N-acetyl-D-glucosamine (GlcNAc) and glucuronic acid (GlcA)
connected by ß(1–4) and ß(1–3) glycosidic bonds in an alter-
nating fashion and forming long chains in the mega-Dalton
range, far surpassing the length of any other GAGs. Unlike
other GAGs, HA is non-sulfonated and does not form covalent
bonds with the protein core in proteoglycans. Instead, HA
binds to specific proteins known as hyaladherins. Examples
of HA-binding proteins (HABPs) are cell surface receptors, such
as the Cluster of Differentiation 44 (CD44), or matrix proteins
like link protein (LP) that connects HA to aggrecan in cartilage
extracellular matrix. HA has been exploited in many biomedical
applications including areas such as ophthalmology, orthopaedics
and drug delivery.2 Currently, ultrapure HA is still obtained by
extraction from natural sources,3 such as rooster combs, bovine
vitreous humour and also from engineered bacteria.4 The
chemical synthesis of this large polysaccharide with precision
and control would be challenging and has never been attempted.
Glycopolymers provide a simpler alternative method to the
total chemical synthesis of glycans (e.g. synthesis of precisely
defined oligosaccharides by chemical glycosylation). They provide
two key components: the sugar moieties, which are biologically
active and recognised by specific proteins, and the stability of a
polymer backbone. Despite the lack of glycosidic bond, glyco-
polymers have been shown to be recognized by carbohydrate-
binding domains in proteins and have been exploited in areas
such as enzyme inhibition.5–7 Many carbohydrate receptors are
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located on the cell surface, allowing the reversible binding of
polymers to multiple receptors. With some receptors inducing
signal transduction upon binding, this weak signal is amplified as
multiple receptors are triggered simultaneously. The multivalency
of glycopolymers permits the formation of strong interactions
with receptors which can be used to dissect the role of structure
and function of natural glycans.8
Advances in synthetic polymerization techniques in the past
two decades allow precise control over the polymerisation pro-
cess. Currently, polymers can be produced with high precision
for dispersity (Ð), degree of polymerisation9,10 (DP) and
sequence11,12 through controlled radical polymerisation meth-
ods, such as reversible addition–fragmentation chain transfer
(RAFT),13,14 atom transfer radical polymerisation (ATRP)15 and
single electron transfer living radical polymerisation (SET-
LRP).16 The synthesis of glycopolymers has been achieved
through click chemistry17 via regioselective and chemoselective
reactions to link the saccharide units to either a monomer,
for pre-polymerisation modification, or orthogonally post-
polymerisation.18,19 With a large array of polymerisation
methods, monomers and chemoselective reactions available, more
complex glycopolymers are being designed and synthesized.20,21
GAG mimetic polymers have been previously synthesised by
methods such as ring-opening metathesis polymerisation
(ROMP) and step-growth polymerisations to form HA-,22
heparan sulfate-(HS)23,24 and chondroitin sulfate-(CS)25,26
based glycopolymers. However, the synthesis of such glyco-
polymers involves challenging multistep reactions resulting in
low yields to produce a disaccharide with a single glycosidic
bond. Herein, glycopolymers bearing single or alternating HA
monosaccharides have been synthesised and used as synthetic
tools to dissect the binding of HA to known and new proteins
and as potential HA-mimetic therapeutics.
Results and discussion
Synthesis and characterisation of glycopolymers
A series of monosaccharides were synthesised (Scheme S1,
ESI†) to display a click moiety at the anomeric centre. This
was achieved by direct glycosylation with an alcohol donor
using H2SO4–silica.
27 However, for GlcA, the monosaccharide
requires acetylation followed by esterification to inhibit the
formation of a bicyclic lactone,28 before using BF3OEt2 as a
catalyst to form the glycosidic bond with the alcohol donor
(Scheme S2, ESI†). The glycopolymers were then synthesised by
first producing a well-defined polymer backbone of poly(4-
vinylbenzyl chloride) (P1) using RAFT polymerisation to give
P1 with a dispersity (Ð) of 1.13 (Scheme 1 and Table 1). The
pendant chloride was converted to azide (P2) and then ‘clicked’
with a monosaccharide alkyne by copper alkyne–azide cycload-
dition (CuAAc), to produce glycohomopolymers (P3–P7) bearing
different sugar monomers (Glc, Man, Gal, GlcNAc, GlcA) and
the statistical glycocopolymer (P8). The formation of the glyco-
polymers was monitored by FT-IR (Fig. S2, ESI†), GPC (Fig. S3,
ESI†) and 1H NMR (Fig. S5, ESI†).
It was noted that during the azidation, a high molecular
weight shoulder appeared in the GPC with peak maximum molar
mass (Mp) double that of the main peaks Mp (Fig. S4, ESI†). The
cleavage of RAFT end group by sodium azide has previously been
reported in the literature.29 Attempts to cleave the RAFT end
group30,31 were ineffective due to the composition of the poly-
mer, inhibiting some cleavage techniques (e.g. styrenic backbone
Scheme 1 Synthetic overview of the pathways for the formation of the homo- and alternating glycopolymers. Reagents and conditions: (a) V601, CTA,
dioxane, 70 1C, 16 h (b) NaN3, DMSO, 16 h (c) Cu(I)Br, Me6TREN, DMSO, 24 h (d) (i) Cu(I)Br, Me6TREN, DMSO, 24 h (ii) K2CO3, H2O.
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and pendant chloride) or provided only partial cleavage detected
by UV detector of the GPC (Fig. S7, ESI†).
Using the styrene-maleic anhydride alternating copolymer
system,2,32,33 a co-monomer of 1-(3-(trimethylsilyl)prop-2ynyl)-1H-
pyrrole-2,5-dione (TMS PMI) was produced using the Mitsunobu
reaction33,34 and added into the RAFT polymerisation medium of
VBC (Fig. S9, ESI†). To ensure the alternation in the co-monomer
composition, the TMS PMI was added in excess to reduce the
potential of VBC block formation within the copolymer. The TMS
group is vital for the polymerisation of the maleimide monomer
as it prevents the crosslinking of chains through the alkyne
(Fig. S8, ESI†) and inhibition of intra or intermolecular cyclisation
of P10 during the first set of the CuAAC reactions.
The alternation was measured by following the poly-
merisation kinetics (Fig. 1A) which showed that over the initial
2 hours, individual polymerisation of VBC and TMS PMI dis-
played no conversion. Extended reaction times produced pVBC,
while TMS PMI showed no conversion. In comparison, a copo-
lymerisation system showed increased polymerisation rate (kp) to
the homopolymers, that were identical to each other. Owing to
the inability of TMS PMI to self-propagate, TMS PMI propagates
after each addition of VBC monomer. The stoichiometric excess
of TMS PMI, along with the identical kp values, indicates a high
degree of alternation. The kinetics also showed good control over
the growing polymer (Fig. 1B) in both molecular weight (Mn) and
dispersity (Ð). Furthermore, Matrix-Assisted Laser Desorption
Ionization Time-of-Flight Mass Spectrometry (MALDI-ToF-MS)
was performed to detect the alternating nature of the copolymer.
Whilst the resolution was limited, individual distributions could
be assigned with the major distribution with a delta of 360 Da,
equivalent to the molecular weight sum of both monomers
(Fig. S1, ESI†). The smaller distributions can be assigned as
polymers being initiated by the radical initiator or by the RAFT
agent with initiation or termination of the polymer with either
TMS-PMI or VBC. Several of the peaks have a secondary peak
32 Da away, this arises from the ring-opening of the maleimide
by methanol during precipitation.
By a similar methodology used for the homoglycopolymers,
the pendant chloride was converted into an azide (P10) and
then ‘clicked’ with a GlcNAc-alkyne by CuAAc to produce an
alternating glycocopolymer. The TMS group can be efficiently
cleaved by supplementing the dialysis with K2CO3.
After which point the resulting polymer (P11) can undergo
CuAAc with GlcA-azide to form the final alternating glycoco-
polymer (P12). The CuAAc click reaction was monitored by
NMR (Fig. 1C), FT-IR (Fig. 1D) and GPC (Fig. S9, ESI†).
Structural and physical properties of HA glycopolymers
All glycopolymers possess a hydrophobic polymer backbone
with orthogonal hydrophilic sugars. Similar glycopolymer sys-
tems have shown to aggregate at low concentration due to
collapse of the hydrophobic polymer backbone.35 To assess the
aggregation behaviour of the glycopolymers in water, fluores-
cence measurements were conducted using Nile red as a
fluorescent reporter. Nile red is a sovatochromic dye that has
very weak fluorescence intensity in pure water, with an emis-
sion maximum at around 660 nm, but when encapsulated in a
hydrophobic environment, it emits strong fluorescence at
around 620 nm (blue shift).36 All the polymers showed a blue
shift and an increase in fluorescent output (Fig. S10, ESI†)
above a certain concentration, inferring a critical aggregation
concentration (CAC). This aggregation affects the hydro-
dynamic volume leading to a decrease in Mn and Ð by GPC
analysis compared to the theoretical values (Table 1). It must be
noted, however, that the CAC was performed in H2O whilst the
GPC was performed in DMF.
The zeta-potential values (z, Fig. 1E) of P7, P8 and P12 show
a net negative charge due to the incorporation of GlcA mono-
saccharide into the glycopolymers, whilst the other glycopoly-
mers (P3–6), which do not possess a charged monosaccharide,
have a near-neutral zeta potential. Collating the CAC of the
glycopolymers and the z-potential results, it can be proposed
that repulsion between the negatively charged GlcA units
resulted in an increase of the CAC by a factor of 10. The
magnitude of the z-potential can also give information relative
to the stability of the aggregates. The z-potential results show
no significant difference between P7 and P8, but P12 exhibits a
considerably larger negative zeta potential. By mimicking the





P1 pVBC56 Homopolymer 12 800 13 100 1.13
P2 pVBAz56 Homopolymer 13 400 13 400 1.20
P3 pVB-Glc56 Glycohomopolymer 32 000 4400 1.07
P4 pVB-Man56 Glycohomopolymer 32 000 4400 1.08
P5 pVB-Gal56 Glycohomopolymer 32 000 4300 1.04
P6 pVB-GlcNAc56 Glycohomopolymer 36 000 6900 1.13
P7 pVB-GlcA56 Glycohomopolymer 35 000 6300 1.02
P8 pVB-GlcA23-co-VB-GlcNAc23 Statistical glycocopolymer 35 500 4100 1.04
P9 pVBC24-alt-TMS PMI24 Alternating copolymer 12 800 19 500 1.57
P10 pVBAz24-alt-TMS PMI24 Alternating copolymer 19 900 18 300 2.40
P11 pVB-GlcNAc24-alt-PMI24 Alternating glycocopolymer 27 000 4800 1.02
P12 pVB-GlcNAc24-alt-PMI-GlcA24 Alternating glycocopolymer 40 000 5700 1.06
a Determined by NMR conversion of each monomer plus the mass of the RAFT agent. b Determined by GPC using NH4BF4 (5 mM) in DMF with PS
calibration. Mn = Number average molecular weight. Ð = dispersity.
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alternation behaviour of the HA backbone, P12 has an even
charge distribution leading to the largest negative z, indicating
the aggregate is more stable. For native HA, a much larger
negative z-potential is observed compared to the glycopolymers
P7, P8 and P12. HA is a polyelectrolyte due to dissociation of the
carboxylic acid of GlcA at physiological pH, which is repeated
regularly across the HA chain at 1 nm intervals.1 Small-angle
x-ray scattering (SAXS) on solutions of the glycopolymers also
suggests differences on polymer’s charge (Fig. 1F). The scattering
pattern of natural HA exhibits a peak which is characteristic of a
salt-free polyelectrolyte solution. This peak, often referred to as a
‘correlation peak’, represents an average distance between the
charged domains in the solution (i.e. the HA chains).37,38 As it
could be expected, due to the near-neutral z-potential values of
the glycopolymers compared with HA, the scattering patterns of
P7, P8 and P12 do not display a correlation peak of a
polyelectrolyte.
A qualitative analysis of the scattering patterns of P6, P7, P8
and P12 could be fitted to the form factor of a semi-flexible
chain (ESI,† eqn (1)).39 The best fits to the model are presented
as solid lines in Fig. S11 (ESI†), and the best-fit parameters are
given in Table S4 (ESI†). For different glycopolymers, the Kuhn
length (B50 Å) and the radius (B15 Å) parameters are similar,
suggesting that the flexibility of the chains does not change.
TEM (Fig. 1G) imaging on glycopolymer solutions above
their CAC (Table S3, ESI†) shows the presence of aggregates.
The glycopolymers displaying GlcA residues (P7, P8 and P12)
form smaller aggregates as observed by TEM and further
Fig. 1 Chemical and structural characterization of synthesized glycopolymers. (A) Kinetics of the two monomers comparing them individually (hollow)
and in a copolymerisation (solid) with (B) control over the polymerisation using RAFT. The resulting polymer is converted to the final alternating
glycopolymer, P12 (orange) as shown by (C) 1H NMR with the reactions being monitored by (D) FT-IR following the conversion of the functional groups
(P9, light blue; P10, teal; P11 grey; P12, orange). (E) Zeta-potential at 100 mM in H2O at pH 7.0, (F) SAXS of the glycopolymers and HA at 200 mM in H2O at
pH 7.0 along with (G) TEM images of the aggregates formed by the HA glycopolymers at 1 mM in H2O at pH 7.0 and stained with uranyl acetate (scale bar
1 mm). Analysed by 2way ANOVA analysis, **** significant at P o 0.0001.
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analysed by ImageJ and DLS (Fig. S12, ESI†) showing a narrow
range. Uranyl acetate was used as a stain for TEM imaging,
which is known to interact with negatively charged groups,
such as carboxylate groups. This might have contributed to the
observed condensed structure of the more anionic glycopoly-
mers (P7, P8 and P12). By contrast, P6 which bears no charge in
the z-potential (Fig. 1E) forms larger aggregates with a wider
range of sizes. This indicates that the balance between the
hydrophobic and pi stacking attractions of the styrene within
the backbone, and the charge repulsion of carboxylate groups
on the GlcA residues, govern the size of the aggregates.
CD44 binding
CD44 is the major HA receptor which binds an octamer of HA
in a groove or cleft on the side of the protein.40 To assess the
ability of the glycopolymers to bind CD44, surface plasmon
resonance (SPR) was used where recombinant human CD44
was coupled to a CM5 dextran chip through amine coupling
(Fig. S13, ESI†). Initial SPR binding experiments were carried
out with 20 kDa HA, but it was seen that the protein became
saturated even at very low concentrations (Fig. S14, ESI†). By
reducing the molecular weight from 20 to 5 kDa, an SPR
sensorgram (Fig. 2A) was obtained showing concentration
dependency, leading to a KD of 0.15 mM, a value lower than
previously reported by SPR (3.4–428 mM).41,42
The two glycopolymers P6 (Fig. 2B) and P7 (Fig. 2C) also
show binding to CD44, with estimated affinities of 0.6 mM to 0.9
mM, respectively, although the value for P6 has low confidence
because no Rmax could be reached and the sensorgrams suggest
irreversible binding on the surface.
Control glycopolymers (P3, P4 and P5) bearing glucose,
mannose and galactose monosaccharides show no binding to
CD44. For the statistical glycocopolymer (P8) and alternating
copolymer (P12, Fig. 2D), no selective binding is observed
despite them both possessing the HA monosaccharides. From
these results, it is clear that CD44 shows selective binding to
the monosaccharides found in HA, but when displayed in a
specific configuration. The conformation of the CD44 binding
cleft may enable enhanced interactions with the linear configu-
ration of HA compared to the spherical aggregates of the
glycopolymers which morphology has been shown to be critical
for binding to other receptors.43,44 The binding of P6 and P7 is
expected to follow a multivalent approach, whereby an
increased number of localised monosaccharides allow for
enhanced binding to receptors. In contrast, the disordered
structures formed by P8 and P12, displaying two monosacchar-
ides, may prevent the multivalent effect.
Peptide binding
Having observed that some HA glycohomopolymers bind to CD44
with an affinity similar to HA, we also tested their ability to
interact with HA-binding peptides. We have used a 12-mer peptide
(GAHWQFNALTVR) named Pep-1, which was discovered by phage
display and shown to bind HA with an affinity (KD) of 1.65 mM.
45
Compared to large proteins, such as CD44, which require their
complex tertiary structure for binding, Pep-1 is able to bind HA
despite the random coil structure shown by circular dichroism
(Fig. S17, ESI†). Peptides are easy to synthesize, and desired
functionalities can be added during synthesis for facile immobi-
lization on surfaces. To enable immobilization on gold surfaces, a
thiol moiety was appended at the peptide N-terminus. The
thiolated Pep-1 (Fig. 3A and Scheme S3, ESI†) was successfully
synthesized and purified as confirmed by HPLC and ESI-MS
analysis (Fig. S16, ESI†). The immobilisation of the peptide onto
a gold surface was confirmed by contact angle (Fig. S18, ESI†) and
SPR (Fig. S19, ESI†) analysis. The binding between a thiol and
gold substrate is much faster compared to the attachment of the
protein by amine coupling onto the cyclodextrin surface (Fig. S13,
ESI†).
SPR results showed Pep-1 binding to 5 kDa HA with a KD =
9.5 mM, a value similar to that originally determined.45 Com-
paring the binding of the glycopolymers to Pep-1 with 5 kDa
HA, the binding of HA is surpassed by P6 (Fig. 3B). P6 contains
Fig. 2 SPR sensorgrams for chips functionalised with CD44 at decreasing
concentrations of analyte from 2000 to 125 nM of (A) HA (5 kDa), (B) P6,
(C) P7 and (D) P12. The SPR experiments were conducted by first passing
buffer flow for 60 seconds, followed by injection of the polymer solution
for 300 seconds (association rate), and lastly buffer flow again for 200
seconds (dissociation rate).
Fig. 3 (A) Chemical structure of thiolated Pep-1 for immobilization on
SPR gold chip. (B) SPR sensorgrams for binding to Pep-1 using HA (5 kDa)
(black) and the glycopolymers of P6 (red), P7 (green), P8 (purple) and P12
(orange) at 2000 nM.
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only GlcNAc, which bears a hydrophobic N-acetyl group and
shows a KD of 68 nM, approximately 140 times more potent at
binding to Pep-1 than HA. Alanine scanning studies on Pep-1
suggested the importance of hydrophobic residues for HA
binding.45
Whilst Pep-1 possess a positive charge, due to the arginine
situated at the C-terminus, no binding was observed with P7
and the other GlcA bearing glycopolymers P8 and P12 (Fig. 3B
and Fig. S20, ESI†). The SPR sensorgrams suggest that the
hypothesis of hydrophobic interaction between HA and Pep-1 is
still confirmed by this analytical technique. Similarly, the other
glycopolymers P3–P5 showed no binding to Pep-1 (Fig. S20,
ESI†), indicating the specificity of Pep-1 towards HA and
specifically the GlcNAc units.
Lectin binding
HA interactions with toll-like receptors (TRLs), immune recep-
tors that participate in the innate defence against bacterial
infection, have been described in the literature.46 For example,
HA oligosaccharides were shown to activate dendritic cells via
TRL-4.47 Therefore, we have extended our binding studies to
lectins, carbohydrate-binding proteins also involved in pathogen
invasion and immune system activation.48 C-type lectins, such as
DC-SIGN, MBL and SP-D, predominantly bind monosaccharides
through the C3 and C4 hydroxides, often mediated by a metal
ion such as calcium.49 However, as lectins are found as clusters
on the cell surface, glycopolymers may be able to bind across
multiple sites and produce an amplified lectin signal.8 Using a
series of these C-type lectins and our SPR assay, HA showed no
specific binding to DC-SIGN, MBL or SP-D, whilst the various
glycopolymers display differing binding specificities for each
lectin (Fig. S21–S23, ESI†).
Dectin-1 (CD369)50,51 is a group V lectin found on the cell
membrane surface and part of the natural killer cell receptor.52
Unlike DC-SIGN, MBL and SP-D, it binds saccharides without
the requirement of a Ca2+ ion and, remarkably, binds b(1–3)
glycans. The binding is enhanced for carbohydrates that also
include b(1–6) bonds. HA possesses both b(1–4) linkages and,
more importantly, a b(1–3) linkage suggesting that HA may
bind to Dectin-1. SPR sensorgrams using Dectin-1 shows that
HA does bind to the lectin (Fig. 4A). Our defined glycopolymer
probes were used to investigate this further. The controls of Glc
(P3), Man (P4) and Gal (P5) show no affinity for Dectin-1
(Fig. S24, ESI†), whereas the glycopolymers of HA did show binding.
Of the two monosaccharides found in HA, a clear preference is
seen for P7 (Fig. 4A) compared to P6. When examining the
crystal structure of the binding site within the lectin, several
hydrophilic residues line the surface of the binding cleft,
including histidine’s and arginine’s which can interact electro-
statically with the carboxylic acid of GlcA, whilst other residues
such as serine and aspartic acids can interact through hydrogen
bonding. When comparing the KD values of the GlcA-containing
glycopolymers P7, P8 and P12, the lowest KD is seen for P7 with
a KD of 2 pM (Fig. S24, ESI†) with a large component of this
contributed by very slow dissociation rates showing that these
interactions are very stable. The results may indicate Dectin-1
has specificity for negatively charge saccharides although this
assumption requires additional investigations.
DEC-205 is a cell surface receptor in dendritic cells and has
been shown to play a role in sensing cell-death.53,54 We tested
the binding of glycopolymers to DEC-205 (Fig. 4B) using SPR
and found that HA bound rather poorly, similar to Dectin-1
(Fig. 4A). Whilst DEC-205 is thought to be a C-type lectin, it
appears to share some binding similarities with Dectin-1 and
CD44 based on the SPR data. The crystal structure for DEC-205
has not been reported, but the literature suggests that DEC-205
is a Man-type lectin.55 When studying the binding patterns, no
specific binding is seen for P4 or P5, but P3 showed binding,
inferring that this lectin is actually a glucose-binding lectin.
This hypothesis is extended by the binding of P6 and P7, which
are glucose-based epimers. When comparing the binding affi-
nities of P6 and P7, an order of magnitude difference is
observed with KD of 100 nM and 17 nM, respectively. These
trends are similar to Dectin-1, suggesting a similar binding
model. The binding affinities are enhanced by the formation
of a statistical copolymer containing both monosaccharides
giving 2 orders of magnitude decrease in KD for P8 (KD =
910 pM) with a further order of magnitude decrease for P12
(KD of 13 pM). This implies the distribution of GlcA is critical
for the binding of HA to DEC-205. The results suggest that
glycopolymers can be designed to enhance interactions with
specific lectins by appropriate spacing of the carboxylic acid
and GlcNAc units. The binding results for all the proteins and
peptide are summarised in Table S5 (ESI†).
Hyaluronidase binding and inhibition
Hyaluronidase (HAase), the enzyme that catalyses the hydro-
lysis of HA by cleavage of b(1–4) glycosidic linkages, plays an
important role in HA turnover in the human body.56 High levels
of HAase are hallmarks in many types of cancer.57,58 Thus,
modulating their activity through inhibitors is critical for
normal homeostasis and for designing cancer therapies. The
potential of the HA mimetic glycopolymers as HAase inhibitors
was evaluated by first assessing their interaction with HAase by
SPR. Heparin, a well-known non-competitive inhibitor of
HAase, which does not bind to the enzyme catalytic site, was
used as a control.59,60 However, the heparin inhibition effects
on HAase activity are achieved for heparin concentrations
higher than the ones present at physiological levels.61
Fig. 4 SPR sensorgrams showing (A) Dectin-1 and (B) DEC-205 binding
to HA (5 kDa) (black) and the glycopolymers of P6 (red), P7 (green), P8
(purple) and P12 (orange) all at 2000 nM.
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The glycopolymers bearing monosaccharides of GlcNAc (P6)
and GlcA (P7) bound to HAase with similar binding profiles as
observed with CD44 (Fig. 2), with the rapid association for P7
and slower, but tighter association for P6 (Fig. 5A and B).
Additionally, the statistical copolymer (P8, Fig. 5C) displayed
a weak interaction with HAase at the highest concentration.
Heparin (Fig. 5D) associated rapidly and showed unmeasurably
slow dissociation. The result infers that electrostatic
interactions62 play an important role in the rate of association
to HAase since heparin, P7 and P8, all possessing negative
charges, associate faster than the neutral P6 glycopolymer
(Table S5, ESI†). The other glycopolymers (P3, P4, P5 and
P12) showed no binding to HAase (Fig. S26, ESI†).
To investigate the potential of glycopolymers as inhibitors of
HAase activity, we have used SPR real-time interaction measure-
ment to monitor binding, inhibition and degradation in a single
run. CD44 was firstly bound to the chip surface to immobilize
HA. HAase was then incubated with appropriate glycopolymers
or heparin before this mixture was injected over the SPR chip
surface. As seen in Fig. 6A, when HAase without inhibitor was
injected into the system, there was a rapid and dramatic
reduction in SPR units showing the total mass decreased on
the chip surface because of the degradation and release of HA.
P5 was used as control glycopolymer as no binding was
observed between P5 and HAase (Fig. S26, ESI†). HA degradation
by HAase proceeds in the presence of P5 (Fig. 6B), as anticipated.
Mixing of HAase with P6 or P7 resulted in additional mass on the
chip suggesting that the HAase could bind HA, but these
glycopolymer–HAase complexes may cause the inactivity or
inhibition of the HAase towards HA degradation (Fig. 6C and
D). Subsequent injection of HAase alone led to resumption of
loss of mass from the chip in both cases. P8 and heparin (Fig. 6E
and F) displayed retardation in the rates of HA degradation and
no rise in mass on the chip surface, which suggests that these
polymers block the ability for HA to bind to the HAase binding
site as part of their mechanism of inhibition.
In summary, even though the SPR results indicate that P6
and P7 displayed stronger inhibition of HAase activity than
heparin, these preliminary results require further investigation
using different techniques to assess the degree and mechanism
of HAase inhibition by these HA glycopolymers.
The diversity of the glycopolymers tested in this study offers
the possibility to probe, in isolation or combination, the effect
of hydrophobic interactions (GlcNAc in P6), electrostatic inter-
actions (GlcA in P7), or both (P8 and P12), on the binding to
protein receptors or the difference between the epimers of Glc-
based (P3, P6, P7, P8 & P12), Man-based (P4) and Gal-based
(P5).
Cytotoxicity of the HA glycopolymers
To extend the utility of the HA glycopolymers as chemical
probes in cell studies, their cytotoxicity was evaluated on
relevant cells, such as LuC4 cells (cell line derived from oral
and skin carcinomas) which express CD44.63 The cell viability
results (Fig. S27A, ESI†) showed that the glycopolymers were
non-toxic to cells. No statistically significant difference was
seen between the control and P6, P7 and P12. Incubation with
P8 resulted in a statistically significant decrease in the normal-
ised fluorescent output of the calcein-AM stain. However, upon
analysis of fluorescence of dead cells stained with ethidium
homodimer-1 (Fig. S27B, ESI†), there was no significant differ-
ence seen between each of the glycopolymers. The results
indicate that the glycopolymers have low cytotoxicity up to a
concentration of 100 mg mL1.
Conclusions
Using controlled polymerization combined with CuAAC click
reaction, HA-based glycopolymers were successfully produced,
Fig. 5 SPR sensorgrams for chips functionalised with HAase challenged
with concentrations of analyte from 2000 to 125 nM of (A) P6, (B) P7, (C)
P8 and (D) heparin.
Fig. 6 SPR measurements showing the inhibitory activity of the glycopo-
lymers against hyaluronidase on the degradation of HA bound to the
immobilized CD44 receptor; (A) without polymer, (B) P5, (C) P6, (D) P7, (E)
P8, and (F) heparin.
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including glycohomopolymers and a statistical polymer based
on HA monosaccharides. Through a selective and orthogonal
reaction, a fully alternating HA glycopolymer was produced
by selective grafting of monosaccharides to each individual
monomer of a modified styrene-maleic anhydride polymer. The
glycopolymers were used as probes to identify monosacchar-
ides involved in the binding interactions with known proteins
(CD44, HAase) and peptides. The HA glycopolymer probes were
further analysed for binding to both classical and non-classical
C-type lectins, confirming that the latter bind to HA. The
backbone stiffness and monosaccharide composition/presenta-
tion were shown to play an important role in the glycopolymer
conformation and in the interaction with HA- and
carbohydrate-binding proteins. Moreover, our studies reveal
the value of HA glycopolymers as potential synthetic inhibitors
of HA-binding proteins.
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